Trial Profile
The Utility of Insulin Glargine (Lantus) Compared to NPH [insulin suspension isophane] in Ethnic Minority Type 2 Diabetic Subjects Starting Insulin Therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 May 2017
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Insulin suspension isophane
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 06 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Feb 2009 Planned end date changed from 1 Feb 2010 to 1 Aug 2009 as reported by ClinicalTrials.gov.